Acorah Software Products - Accounts Production 16.3.350 false true false 18 January 2024 31 December 2024 31 December 2024 15423511 Ms CHUNYU XIU iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15423511 2024-01-17 15423511 2024-12-31 15423511 2024-01-18 2024-12-31 15423511 frs-core:CurrentFinancialInstruments 2024-12-31 15423511 frs-core:ShareCapital 2024-12-31 15423511 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 15423511 frs-bus:PrivateLimitedCompanyLtd 2024-01-18 2024-12-31 15423511 frs-bus:FilletedAccounts 2024-01-18 2024-12-31 15423511 frs-bus:SmallEntities 2024-01-18 2024-12-31 15423511 frs-bus:AuditExempt-NoAccountantsReport 2024-01-18 2024-12-31 15423511 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-18 2024-12-31 15423511 frs-bus:Director1 2024-01-18 2024-12-31 15423511 frs-countries:EnglandWales 2024-01-18 2024-12-31
Registered number: 15423511
Biomarker Technologies (Bmkgene) UK Ltd
Unaudited Financial Statements
For the Period 18 January 2024 to 31 December 2024
LABAIT PROFESSIONALS LIMITED
Institute of Financial Accountants
Unit 1 17 Castle Street
Chester
CH1 2DS
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2—3
Page 1
Balance Sheet
Registered number: 15423511
31 December 2024
Notes £ £
CURRENT ASSETS
Debtors 4 8,090
Cash at bank and in hand 74,132
82,222
Creditors: Amounts Falling Due Within One Year 5 (95,371 )
NET CURRENT ASSETS (LIABILITIES) (13,149 )
TOTAL ASSETS LESS CURRENT LIABILITIES (13,149 )
NET LIABILITIES (13,149 )
CAPITAL AND RESERVES
Called up share capital 6 1
Profit and Loss Account (13,150 )
SHAREHOLDERS' FUNDS (13,149)
For the period ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Ms CHUNYU XIU
Director
19/08/2025
The notes on pages 2 to 3 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Biomarker Technologies (Bmkgene) UK Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15423511 . The registered office is Block 19, 19f - Lab 1 Alderley Park, Congleton Road, Nether Alderley, Macclesfield, Cheshire, SK10 4TG.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Financial Instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments FRS 102' to all of its financial instrument.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liability are offset, with the net amounts present in the financial statements, when there is a legal enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets, which include debtors and cash and bank balance, and initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidence a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitute a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instrument are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
3. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
Page 2
Page 3
4. Debtors
31 December 2024
£
Due within one year
Prepayments and accrued income 1,585
Other debtors 3,910
VAT 2,595
8,090
5. Creditors: Amounts Falling Due Within One Year
31 December 2024
£
Other loans 94,076
Other creditors 1,295
95,371
6. Share Capital
31 December 2024
£
Allotted, Called up and fully paid 1
7. Related Party Transactions
During the year, two related-party loan transactions occurred.
The first loan was made between BIOMARKER TECHNOLOGIES (BMKGENE) UK LTD and BIOMARKER TECHNOLOGIES (HONG KONG) COMPANY LIMITED.  BIOMARKER TECHNOLOGIES (HONG KONG) COMPANY LIMITED is the sole shareholder of the UK company.  BIOMARKER TECHNOLOGIES (BMKGENE) UK LTD borrowed a total of £40,000 from BIOMARKER TECHNOLOGIES(HONGKONG)COMPANY LIMITED and used £1 to pay the ordinary share capital.
The second loan was made between BIOMARKER TECHNOLOGIES (BMKGENE) UK LTD and BIOMARKER TECHNOLOGIES (BMK) GMBH.  BIOMARKER TECHNOLOGIES (BMKGENE) UK LTD borrowed a total of £60,000 from BIOMARKER TECHNOLOGIES
(BMK) GMBH.  Meanwhile,  BIOMARKER TECHNOLOGIES (BMKGENE) UK LTD paid expenses amounting to £5,923.04 on behalf of BIOMARKER TECHNOLOGIES (BMK) GMBH.
At the year-end, the loan balance between the UK company and the Hong Kong shareholder was £40,000, and the balance between the UK company and the German branch was £54,076.96.
Page 3